Literature DB >> 15951394

Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure.

R J Shelton1, A S Rigby, J G F Cleland, A L Clark.   

Abstract

OBJECTIVE: To determine the pattern of beta blocker prescribing over one year in a heart failure clinic with a structured approach towards initiation and dose titration and to give a real life perspective on beta blocker use, compliance, and target dose achievement.
METHODS: Data were retrospectively analysed on 513 consecutive patients regularly attending a community heart failure clinic over a year. Systolic dysfunction was determined from two dimensional echocardiography (left ventricular ejection fraction < or = 40%) and lung function was assessed by spirometry. All patients were considered for beta blocker initiation and dose up titration.
RESULTS: Within one year 157 patients died. 143 patients started beta blockers resulting in 315 (88%) patients taking beta blockers at one year; 38% were taking the target dose. 124 had evidence of airways obstruction at baseline, 100 (81%) of whom were taking beta blockers at one year. Forced expiratory volume in one second (1.1 v 1.5 l, p < 0.01) and forced vital capacity (2.3 v 2.5 l/min, p = 0.2) were not reduced in patients with airways obstruction who received beta blockers. Daily doses of beta blockers at one year did not differ statistically between patients with obstructive and patients with non-obstructive spirometry results. 12 patients discontinued beta blockers and 14 required dose reduction due to side effects.
CONCLUSION: The majority of patients with heart failure and obstructive airways disease can safely tolerate low dose initiation and gradual up titration of beta blockers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951394      PMCID: PMC1860814          DOI: 10.1136/hrt.2004.059758

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  34 in total

1.  Statistical methods in epidemiology. III. The odds ratio as an approximation to the relative risk.

Authors:  A S Rigby
Journal:  Disabil Rehabil       Date:  1999-04       Impact factor: 3.033

2.  Spectrum of heart failure in older patients: results from the National Heart Failure project.

Authors:  Edward P Havranek; Frederick A Masoudi; Kelly A Westfall; Pam Wolfe; Diana L Ordin; Harlan M Krumholz
Journal:  Am Heart J       Date:  2002-03       Impact factor: 4.749

3.  Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF).

Authors:  Stephen S Gottlieb; Michael L Fisher; John Kjekshus; Prakash Deedwania; Lars Gullestad; Jiri Vitovec; John Wikstrand
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

4.  The current cost of heart failure to the National Health Service in the UK.

Authors:  Simon Stewart; Andrew Jenkins; Scot Buchan; Alistair McGuire; Simon Capewell; John J J V McMurray
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

5.  Outpatient adherence to beta-blocker therapy after acute myocardial infarction.

Authors:  Javed Butler; Patrick G Arbogast; Rhonda BeLue; James Daugherty; Manoj K Jain; Wayne A Ray; Marie R Griffin
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

6.  Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey.

Authors:  J G F Cleland; A Cohen-Solal; J Cosin Aguilar; R Dietz; J Eastaugh; F Follath; N Freemantle; A Gavazzi; W H van Gilst; F D R Hobbs; J Korewicki; H C Madeira; I Preda; K Swedberg; J Widimsky
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

7.  Effect of carvedilol on survival in severe chronic heart failure.

Authors:  M Packer; A J Coats; M B Fowler; H A Katus; H Krum; P Mohacsi; J L Rouleau; M Tendera; A Castaigne; E B Roecker; M K Schultz; D L DeMets
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

8.  Baseline predictors of tolerability to carvedilol in patients with chronic heart failure.

Authors:  H Krum; D Ninio; P MacDonald
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

Review 9.  Cardioselective beta-blockers for chronic obstructive pulmonary disease.

Authors:  S S Salpeter; T Ormiston; E Salpeter; P Poole; C Cates
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.

Authors:  Eugene Kotlyar; Anne M Keogh; Peter S Macdonald; Ruth H Arnold; Dermot J McCaffrey; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2002-12       Impact factor: 10.247

View more
  9 in total

1.  The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure.

Authors:  Mitja Lainscak; Lea Majc Hodoscek; Hans-Dirk Düngen; Mathias Rauchhaus; Wolfram Doehner; Stefan D Anker; Stephan von Haehling
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 2.  Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.

Authors:  Abhishek Jaiswal; Astha Chichra; Vinh Q Nguyen; Taraka V Gadiraju; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2016-02

3.  Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community.

Authors:  Noel O'Kelly; William Robertson; Jude Smith; Jonathan Dexter; Collette Carroll-Hawkins; Sudip Ghosh
Journal:  World J Cardiol       Date:  2012-03-26

4.  Acute heart failure with accompanying chronic obstructive pulmonary disease: should we focus on beta blockers?

Authors:  M R Ege; U Guray; Y Guray; M B Yilmaz; O Yucel; A Zorlu; I Tandogan
Journal:  Herz       Date:  2012-06-16       Impact factor: 1.443

5.  Trends and inequities in beta-blocker prescribing for heart failure.

Authors:  Sunil M Shah; Iain M Carey; Stephen DeWilde; Nicky Richards; Derek G Cook
Journal:  Br J Gen Pract       Date:  2008-12       Impact factor: 5.386

Review 6.  Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues.

Authors:  Miranda R Andrus; Joyce V Loyed
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting.

Authors:  Jennifer J Schimmer; Sarah J Billups; Thomas Delate
Journal:  Pharm Pract (Granada)       Date:  2009-03-15

Review 8.  Carvedilol in the treatment of elderly patients with chronic heart failure.

Authors:  Klaus K A Witte; Andrew L Clark
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

9.  Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) - Polish population.

Authors:  Ewa Straburzyńska-Migaj; Marta Kałużna-Oleksy; Aldo Pietro Maggioni; Stefan Grajek; Grzegorz Opolski; Piotr Ponikowski; Ewa Jankowska; Paweł Balsam; Lech Poloński; Jarosław Drożdż
Journal:  Arch Med Sci       Date:  2015-01-14       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.